Abbisko Cayman Limited ( ($HK:2256) ) has shared an announcement. Abbisko Therapeutics, a subsidiary of Abbisko Cayman Limited, presented ...

Chimeric Antigen Receptor (CAR) T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of ...

Scientists found that nearly every cancer harbors its own distinct community of microbes – tiny passengers that can influence how tumors start, spread, and respond to treatment, paving the way for a ...

This activity has been designed to address the educational needs of sports medicine clinicians (physicians and advanced practice providers), orthopedic surgeons, and medical and surgical oncology ...

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety ...

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today ...

Vimseltinib is the first and only therapy with marketing authorization for the treatment of TGCT in the European Union Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: ...

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the European Commission (EC) has approved ROMVIMZA™ (vimseltinib) in the ...

Objective To retrospectively compare the impact of using neoadjuvant denosumab forCampanacci grade-III giant cell tumor(GCT) of the proximal femur involving the hip joint. Methods We retrospectively ...